Where to Start? Setting Your Medical Writing Team Up for Success with GenAI Blog Post
Summary Generative AI (GenAI) is poised to revolutionize writing and report generation. In fact, industry studies have shown the use of GenAI can introduce efficiencies of up to 40% while...
Optimizing DDI Knowledge throughout Drug Development Blog Post
An Introduction to Certara’s Drug Interaction Database (DIDB) Speakers: Isabelle Ragueneau-Majlessi, MD, MS Distinguished Scientist Jingjing Yu, MD, PhD Director Learn more about Drug Interaction Database (DIDB®) The industry’s largest...
From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations Blog Post
Karen Rowland Yeo SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client & Regulatory Strategy at Certara UK Limited’s Simcyp Division. She has over two...
Projet COVID-19 – Note d’information collective Page
Projet COVID-19 – Note d’information collective View FullscreenNote d’information collective relative à la protection des données personnelles dans le cadre des études nécessitant l’accès aux données du Système National des Données de Santé (SNDS) Page
Note d’information collective relative à la protection des données personnelles dans le cadre des études nécessitant l’accès aux données du Système National des Données de Santé (SNDS) View Fullscreen
Streamlining the Preparation of 1-Year and 2-Year PSURs Blog Post
We explore how we helped one client deliver a last-minute addition to a Periodic Safety Update Report and identify the need for an additional 2-year PSUR.
Certara Launches v12.0 of SEND Explorer Blog Post
2024年12月18日 Expanded visualizations and data standards support workflows for preclinical scientists and toxicologists Radnor, PA – 2024年12月18日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, announced...
